id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-293711-qgefn164	Abdelmaksoud, Ayman	Comment on “COVID‐19 and psoriasis: Is it time to limit treatment with immunosuppressants? A call for action”	2020-04-16		.txt	text/plain	667	48	37	apy their recommendations for treatment of patients with psoriasis at time of new COVID-19 pandemic. The authors pointed to the importance of therapeutic reassessment of all psoriatic patients, particularly those with moderate-to-severe disease, who are candidate to systemic, mostly immunosuppressive, therapies in the era of COVID-19. COVID-19 virus has neurotropic potential that partially explains the higher rate of acute respiratory distress in elderly patients. ultraviolet A1 (UVA1) phototherapy has a comparable efficacy in moderate-to-severe plaque-type psoriasis and could improve the clinical manifestations and quality of life more quickly than narrow band ultraviolet B therapy with no significant side effects, including lack of increased risk of cutaneous malignancies. COVID-19 and psoriasis: is it time to limit treatment with immunosuppressants? Older adults on systemic treatment for psoriasis and risk of infection:a propensity score matched population-based study Risk of serious infection in patients receiving systemic medications for the treatment of psoriasis Should patients stop their biologic treatment during the COVID-19 pandemic	./cache/cord-293711-qgefn164.txt	./txt/cord-293711-qgefn164.txt